Report cover image

US and Europe Metastases Spinal Tumor Market Research Report Forecast to 2030

Publisher Market Research Future
Published Oct 18, 2023
Length 114 Pages
SKU # RESFT18269042

Description

US and Europe Metastases Spinal Tumor Market Research Report Forecast to 2030


The growth of the US and Europe metastases spinal tumor market is attributed to the increasing incidences of metastases spinal tumor and the launch of the research start-up programme. However, the side effects associated with spine tumor treatments are anticipated to hamper the market growth.

Metastatic spinal tumors are abnormal tissue clusters that can develop in the spine or adjacent to the spinal cord. More than 95% of metastatic spinal tumors are found extradural or within the vertebral body, and more than 50% of the time, they are found on multiple levels of the spine. These types of cancer are also referred to as secondary spinal tumors or spinal metastases. Moreover, primary spinal tumors are tumors that begin in the spinal column. They are quite rare, mostly benign (noncancerous), and make up a minor portion of spinal tumors.

The increasing incidences of metastases spinal tumor and the launch of the research start-up programme are imperative factors driving the growth of the US and European metastases spinal tumor market. However, the side effects associated with spine tumor treatment are restraining the growth of the US and Europe metastases spinal tumor market. Nonetheless, it is anticipated that ongoing clinical trials will create lucrative opportunities for the players operating in the US and Europe metastases spinal tumor market.

Market Segmentation
Based on type, the US and Europe Metastases Spinal Tumor Market have been segmented into extradural, intradural-extramedullary, and intramedullary.

Based on Diagnosis & Treatment, the US and Europe metastases spinal tumor market has segmented diagnosis, and treatment. The treatment segment dominated the market in 2022 and the diagnosis segment is projected to be the fastest growing segment during the forecast period, 2023–2030.

Based on end user, the US and Europe Metastases Spinal Tumor Market has been segmented into hospital & clinics, ambulatory surgery centers, research & academic institutes, and others.

The Europe metastases spinal tumor market held the largest market in 2022 with a market share of 51.32% and US is projected to be the fastest growing country during the forecast period.

Major Players
GE Healthcare (US), Medtronic Plc (Ireland), Amgen Inc (US), Siemens Healthineers AG (Germany), and Stryker (US), Merit Medical Systems (US), Brainlab AG (Germany), Johnson & Johnson Services Inc (US), Zimmer Biomet (US), and Shimadzu Corporation (Japan).

Companies Mentioned
GE Healthcare (US)
Medtronic Plc (Ireland)
Amgen Inc (US)
Siemens Healthineers AG (Germany)
and Stryker (US)
Merit Medical Systems (US)
Brainlab AG (Germany)
Johnson & Johnson Services Inc (US)
Zimmer Biomet (US)
and Shimadzu Corporation (Japan).

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

114 Pages
1 Executive Summary 13
1.1 Overview 13
2 Market Introduction 14
2.1 Definition 14
2.2 Scope Of The Study 14
2.3 Research Objective 14
2.4 Market Structure 15
2.5 Assumptions & Limitations 15
3 Research Methodology 16
3.1 Data Mining 16
3.2 Secondary Research 17
3.3 Primary Research 18
3.4 Breakdown Of Primary Respondents 19
3.5 Forecasting Techniques 19
3.6 Research Methodology For Market Size Estimation 20
3.6.1 Bottom-up Approach 21
3.6.2 Top-down Approach 22
3.7 Data Triangulation 23
3.8 Validation 23
4 Market Dynamics 24
4.1 Overview 24
4.2 Drivers 25
4.2.1 Increasing Incidences Of Metastases Spinal Tumor 25
4.2.2 Launch Of The Research Start-up Programme 25
4.3 Restraints 26
4.3.1 Side Effects Associated With Spine Tumor Treatments 26
4.4 Opportunities 26
4.4.1 Ongoing Clinical Trials 26
4.4.2 Launch Of Research Centres And Support For Research Funding 27
5 Market Factor Analysis 28
5.1 Value Chain Analysis 28
5.1.1 R&D 29
5.1.2 Manufacturing 29
5.1.3 Distribution & Sales 29
5.1.4 Post-sales Monitoring 29
5.2 Porter's Five Forces Model 30
5.2.1 Threat Of New Entrants 30
5.2.2 Bargaining Power Of Suppliers 31
5.2.3 Threat Of Substitutes 31
5.2.4 Bargaining Power Of Buyers 31
5.2.5 Intensity Of Rivalry 31
5.3 Impact Of Covid-19 On The Us And Europe Metastases Spinal Tumor Market 32
5.3.1 Impact On Supply Chain 32
5.3.2 Impact On Market Players 32
6 Us And Europe Metastases Spinal Tumor Market, By Type 33
6.1 Overview 33
6.2 Extradural 35
6.3 Intradural-extramedullary 36
6.4 Intramedullary 36
7 Us And Europe Metastases Spinal Tumor Market, By Diagnosis & Treatment 37
7.1 Overview 37
7.2 Diagnosis 39
7.2.1 Imaging Tests 40
7.2.1.1 X-ray 40
7.2.1.2 Computed Tomography (Ct Scan) 41
7.2.1.3 Magnetic Resonance Imaging (Mri Scan) 41
7.2.1.4 Angiography 41
7.2.1.5 F-18 Fluorodeoxyglucose Positron Emission Tomography 42
7.2.1.6 Others 42
7.2.2 Biopsy 42
7.2.3 Others 43
7.3 Treatment 43
7.3.1 Non Operative Treatment 44
7.3.1.1 Medications 44
7.3.1.2 Radiation Therapy 45
7.3.1.3 Ablation 45
7.3.1.4 Chemotherapy 45
7.3.2 Surgical Treatment 46
7.3.2.1 Minimally Invasive Surgery 46
7.3.2.2 Open Surgery 47
8 Us And Europe Metastases Spinal Tumor Market, By End User 48
8.1 Overview 48
8.2 Hospital And Clinics 50
8.3 Ambulatory Surgery Centers 51
8.4 Research & Academic Institutes 51
8.5 Others 51
9 Us And Europe Metastases Spinal Tumor Market, By Region/Country 52
9.1 Overview 52
9.2 Us 54
9.3 Europe 57
9.3.1 Germany 62
9.3.2 France 64
9.3.3 Uk 67
9.3.4 Italy 70
9.3.5 Spain 72
9.3.6 Rest Of Europe 75
10 Competitive Landscape 78
10.1 Overview 78
10.2 Competitive Benchmarking 79
10.3 Major Growth Strategy In The Us And Europe Metastases Spinal Tumor Market 80
10.4 The Leading Player In Terms Of The Number Of Developments In The Us And Europe Metastases Spinal Tumor Market 80
10.5 Key Developments & Growth Strategies 81
10.5.1 Product Approval And Product Launch 81
10.6 Major Players Sales Analysis 81
10.6.1 Sales 81
10.6.2 Major Players R&D Analysis 82
11 Company Profiles 83
11.1 Ge Healthcare 83
11.1.1 Company Overview 83
11.1.2 Financial Overview 84
11.1.3 Products Offered 84
11.1.4 Key Developments 85
11.1.5 Swot Analysis 85
11.1.6 Key Strategies 85
11.2 Siemens Healthineers Ag 86
11.2.1 Company Overview 86
11.2.2 Financial Overview 87
11.2.3 Products Offered 87
11.2.4 Key Developments 88
11.2.5 Key Strategies 88
11.3 Shimadzu Corporation 89
11.3.1 Company Overviews 89
11.3.2 Financial Overview 90
11.3.3 Products Offered 90
11.3.4 Key Developments 91
11.3.5 Key Strategies 91
11.4 Zimmer Biomet 92
11.4.1 Company Overview 92
11.4.2 Financial Overview 93
11.4.3 Products Offered 93
11.4.4 Key Developments 94
11.4.5 Swot Analysis 94
11.4.6 Key Strategies 94
11.5 Johnson & Johnson Services, Inc 95
11.5.1 Company Overview 95
11.5.2 Financial Overview 96
11.5.3 Products Offered 96
11.5.4 Key Developments 97
11.5.5 Key Strategies 97
11.6 Merit Medical Systems 98
11.6.1 Company Overview 98
11.6.2 Financial Overview 99
11.6.3 Products Offered 99
11.6.4 Key Developments 100
11.6.5 Swot Analysis 100
11.6.6 Key Strategies 100
11.7 Amgen Inc. 101
11.7.1 Company Overview 101
11.7.2 Financial Overview 102
11.7.3 Products Offered 102
11.7.4 Key Developments 103
11.7.5 Key Strategies 103
11.8 Stryker 104
11.8.1 Company Overview 104
11.8.2 Financial Overview 105
11.8.3 Products Offered 106
11.8.4 Key Developments 106
11.8.5 Swot Analysis 107
11.8.6 Key Strategies 107
11.9 Medtronic Plc 108
11.9.1 Company Overview 108
11.9.2 Financial Overview 109
11.9.3 Products Offered 109
11.9.4 Key Developments 110
11.9.5 Swot Analysis 110
11.9.6 Key Strategies 110
11.10 Brainlab Ag 111
11.10.1 Company Overview 111
11.10.2 Financial Overview 111
11.10.3 Products Offered 111
11.10.4 Key Developments 111
11.10.5 Key Strategies 111
12 Appendix 112
12.1 References 112
12.2 Related Reports 113
List Of Tables
Table 1 List Of Assumptions & Limitations 15
Table 2 Primary Interviews And Information Gathering Process 18
Table 3 Us And Europe Metastases Spinal Tumor Market, By Type, 2019–2030(Usd Million) 35
Table 4 Us And Europe Metastases Spinal Tumor Market, For Extradural, By Region/Country, 2019–2030(Usd Million) 35
Table 5 Us And Europe Metastases Spinal Tumor Market, For Intradural-extramedullary, By Region/Country, 2019–2030(Usd Million) 36
Table 6 Us And Europe Metastases Spinal Tumor Market, For Intramedullary, By Region/Country, 2019–2030(Usd Million) 36
Table 7 Us And Europe Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2019–2030(Usd Million) 38
Table 8 Us And Europe Metastases Spinal Tumor Market, For Diagnosis, By Region/Country, 2019–2030(Usd Million) 39
Table 9 Us And Europe Metastases Spinal Tumor Market, For Diagnosis, By Type, 2019–2030(Usd Million) 39
Table 10 Us And Europe Metastases Spinal Tumor Market, For Imaging Tests, By Region/Country, 2019–2030(Usd Million) 40
Table 11 Us And Europe Metastases Spinal Tumor Market, For Imaging Tests, By Type, 2019–2030(Usd Million) 40
Table 12 Us And Europe Metastases Spinal Tumor Market, For X-ray, By Region/Country, 2019–2030(Usd Million) 40
Table 13 Us And Europe Metastases Spinal Tumor Market, For Computed Tomography (Ct Scan), By Region/Country, 2019–2030(Usd Million) 41
Table 14 Us And Europe Metastases Spinal Tumor Market, For Magnetic Resonance Imaging (Mri Scan), By Region/Country, 2019–2030(Usd Million) 41
Table 15 Us And Europe Metastases Spinal Tumor Market, For Angiography, By Region/Country, 2019–2030(Usd Million) 41
Table 16 Us And Europe Metastases Spinal Tumor Market, For F-18 Fluorodeoxyglucose Positron Emission Tomography, By Region/Country, 2019–2030(Usd Million) 42
Table 17 Us And Europe Metastases Spinal Tumor Market, For Others, By Region/Country, 2019–2030(Usd Million) 42
Table 18 Us And Europe Metastases Spinal Tumor Market, For Biopsy, By Region/Country, 2019–2030(Usd Million) 42
Table 19 Us And Europe Metastases Spinal Tumor Market, For Others, By Region/Country, 2019–2030(Usd Million) 43
Table 20 Us And Europe Metastases Spinal Tumor Market, For Treatment, By Region/Country, 2019–2030(Usd Million) 43
Table 21 Us And Europe Metastases Spinal Tumor Market, For Treatment, By Type, 2019–2030(Usd Million) 43
Table 22 Us And Europe Metastases Spinal Tumor Market, For Non Operative Treatment, By Region/Country, 2019–2030(Usd Million) 44
Table 23 Us And Europe Metastases Spinal Tumor Market, For Non Operative Treatment, By Type, 2019–2030(Usd Million) 44
Table 24 Us And Europe Metastases Spinal Tumor Market, For Medications, By Region/Country, 2019–2030(Usd Million) 44
Table 25 Us And Europe Metastases Spinal Tumor Market, For Radiation Therapy, By Region/Country, 2019–2030(Usd Million) 45
Table 26 Us And Europe Metastases Spinal Tumor Market, For Ablation, By Region/Country, 2019–2030(Usd Million) 45
Table 27 Us And Europe Metastases Spinal Tumor Market, For Chemotherapy, By Region/Country, 2019–2030(Usd Million) 45
Table 28 Us And Europe Metastases Spinal Tumor Market, For Surgical Treatment, By Region/Country, 2019–2030(Usd Million) 46
Table 29 Us And Europe Metastases Spinal Tumor Market, For Surgical Treatment, By Type, 2019–2030(Usd Million) 46
Table 30 Us And Europe Metastases Spinal Tumor Market, For Minimally Invasive Surgery, By Region/Country, 2019–2030(Usd Million) 46
Table 31 Us And Europe Metastases Spinal Tumor Market, For Open Surgery, By Region/Country, 2019–2030(Usd Million) 47
Table 32 Us And Europe Metastases Spinal Tumor Market, By End User 2019–2030(Usd Million) 50
Table 33 Us And Europe Metastases Spinal Tumor Market, For Hospital And Clinics, By Region/Country, 2019–2030(Usd Million) 50
Table 34 Us And Europe Metastases Spinal Tumor Market, For Ambulatory Surgery Centers, By Region/Country, 2019–2030(Usd Million) 51
Table 35 Us And Europe Metastases Spinal Tumor Market, For Research & Academic Institutes, By Region/Country, 2019–2030(Usd Million) 51
Table 36 Us And Europe Metastases Spinal Tumor Market, For Others, By Region/Country, 2019–2030(Usd Million) 51
Table 37 Us & Europe: Metastases Spinal Tumor Market, By Region/Country, 2019–2030 (Usd Million) 53
Table 38 Us: Metastases Spinal Tumor Market, By Type, 2019–2030 (Usd Million) 54
Table 39 Us: Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2019–2030 (Usd Million) 55
Table 40 Us: Metastases Spinal Tumor Market, For Diagnosis, By Type, 2019–2030 (Usd Million) 55
Table 41 Us: Metastases Spinal Tumor Market, For Imaging Tests, By Type, 2019–2030 (Usd Million) 55
Table 42 Us: Metastases Spinal Tumor Market, For Treatment, By Type, 2019–2030 (Usd Million) 56
Table 43 Us: Metastases Spinal Tumor Market, For Non-operative Treatment, By Type, 2019–2030 (Usd Million) 56
Table 44 Us: Metastases Spinal Tumor Market, For Surgical Treatment, By Type, 2019–2030 (Usd Million) 56
Table 45 Us: Metastases Spinal Tumor Market, By End User, 2019–2030 (Usd Million) 57
Table 46 Europe: Metastases Spinal Tumor Market, By Country, 2019–2030 (Usd Million) 58
Table 47 Europe: Metastases Spinal Tumor Market, By Type, 2019–2030 (Usd Million) 59
Table 48 Europe: Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2019–2030 (Usd Million) 59
Table 49 Europe: Metastases Spinal Tumor Market, For Diagnosis, By Type, 2019–2030 (Usd Million) 60
Table 50 Europe: Metastases Spinal Tumor Market, For Imaging Tests, By Type, 2019–2030 (Usd Million) 60
Table 51 Europe: Metastases Spinal Tumor Market, For Treatment, By Type, 2019–2030 (Usd Million) 60
Table 52 Europe: Metastases Spinal Tumor Market, For Non-operative Treatment, By Type, 2019–2030 (Usd Million) 61
Table 53 Europe: Metastases Spinal Tumor Market, For Surgical Treatment, By Type, 2019–2030 (Usd Million) 61
Table 54 Europe: Metastases Spinal Tumor Market, By End User, 2019–2030 (Usd Million) 61
Table 55 Germany: Metastases Spinal Tumor Market, By Type, 2019–2030 (Usd Million) 62
Table 56 Germany: Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2019–2030 (Usd Million) 62
Table 57 Germany: Metastases Spinal Tumor Market, For Diagnosis, By Type, 2019–2030 (Usd Million) 62
Table 58 Germany: Metastases Spinal Tumor Market, For Imaging Tests, By Type, 2019–2030 (Usd Million) 63
Table 59 Germany: Metastases Spinal Tumor Market, For Treatment, By Type, 2019–2030 (Usd Million) 63
Table 60 Germany: Metastases Spinal Tumor Market, For Non-operative Treatment, By Type, 2019–2030 (Usd Million) 63
Table 61 Germany: Metastases Spinal Tumor Market, For Surgical Treatment, By Type, 2019–2030 (Usd Million) 64
Table 62 Germany: Metastases Spinal Tumor Market, By End User, 2019–2030 (Usd Million) 64
Table 63 France: Metastases Spinal Tumor Market, By Type, 2019–2030 (Usd Million) 64
Table 64 France: Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2019–2030 (Usd Million) 65
Table 65 France: Metastases Spinal Tumor Market, For Diagnosis, By Type, 2019–2030 (Usd Million) 65
Table 66 France: Metastases Spinal Tumor Market, For Imaging Tests, By Type, 2019–2030 (Usd Million) 65
Table 67 France: Metastases Spinal Tumor Market, For Treatment, By Type, 2019–2030 (Usd Million) 66
Table 68 France: Metastases Spinal Tumor Market, For Non-operative Treatment, By Type, 2019–2030 (Usd Million) 66
Table 69 France: Metastases Spinal Tumor Market, For Surgical Treatment, By Type, 2019–2030 (Usd Million) 66
Table 70 France: Metastases Spinal Tumor Market, By End User, 2019–2030 (Usd Million) 67
Table 71 Uk: Metastases Spinal Tumor Market, By Type, 2019–2030 (Usd Million) 67
Table 72 Uk: Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2019–2030 (Usd Million) 67
Table 73 Uk: Metastases Spinal Tumor Market, For Diagnosis, By Type, 2019–2030 (Usd Million) 68
Table 74 Uk: Metastases Spinal Tumor Market, For Imaging Tests, By Type, 2019–2030 (Usd Million) 68
Table 75 Uk: Metastases Spinal Tumor Market, For Treatment, By Type, 2019–2030 (Usd Million) 68
Table 76 Uk: Metastases Spinal Tumor Market, For Non-operative Treatment, By Type, 2019–2030 (Usd Million) 69
Table 77 Uk: Metastases Spinal Tumor Market, For Surgical Treatment, By Type, 2019–2030 (Usd Million) 69
Table 78 Uk: Metastases Spinal Tumor Market, By End User, 2019–2030 (Usd Million) 69
Table 79 Italy: Metastases Spinal Tumor Market, By Type, 2019–2030 (Usd Million) 70
Table 80 Italy: Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2019–2030 (Usd Million) 70
Table 81 Italy: Metastases Spinal Tumor Market, For Diagnosis, By Type, 2019–2030 (Usd Million) 70
Table 82 Italy: Metastases Spinal Tumor Market, For Imaging Tests, By Type, 2019–2030 (Usd Million) 71
Table 83 Italy: Metastases Spinal Tumor Market, For Treatment, By Type, 2019–2030 (Usd Million) 71
Table 84 Italy: Metastases Spinal Tumor Market, For Non-operative Treatment, By Type, 2019–2030 (Usd Million) 71
Table 85 Italy: Metastases Spinal Tumor Market, For Surgical Treatment, By Type, 2019–2030 (Usd Million) 72
Table 86 Italy: Metastases Spinal Tumor Market, By End User, 2019–2030 (Usd Million) 72
Table 87 Spain: Metastases Spinal Tumor Market, By Type, 2019–2030 (Usd Million) 72
Table 88 Spain: Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2019–2030 (Usd Million) 73
Table 89 Spain: Metastases Spinal Tumor Market, For Diagnosis, By Type, 2019–2030 (Usd Million) 73
Table 90 Spain: Metastases Spinal Tumor Market, For Imaging Tests, By Type, 2019–2030 (Usd Million) 73
Table 91 Spain: Metastases Spinal Tumor Market, For Treatment, By Type, 2019–2030 (Usd Million) 74
Table 92 Spain: Metastases Spinal Tumor Market, For Non-operative Treatment, By Type, 2019–2030 (Usd Million) 74
Table 93 Spain: Metastases Spinal Tumor Market, For Surgical Treatment, By Type, 2019–2030 (Usd Million) 74
Table 94 Spain: Metastases Spinal Tumor Market, By End User, 2019–2030 (Usd Million) 75
Table 95 Rest Of Europe: Metastases Spinal Tumor Market, By Type, 2019–2030 (Usd Million) 75
Table 96 Rest Of Europe: Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2019–2030 (Usd Million) 75
Table 97 Rest Of Europe: Metastases Spinal Tumor Market, For Diagnosis, By Type, 2019–2030 (Usd Million) 76
Table 98 Rest Of Europe: Metastases Spinal Tumor Market, For Imaging Tests, By Type, 2019–2030 (Usd Million) 76
Table 99 Rest Of Europe: Metastases Spinal Tumor Market, For Treatment, By Type, 2019–2030 (Usd Million) 76
Table 100 Rest Of Europe: Metastases Spinal Tumor Market, For Non-operative Treatment, By Type, 2019–2030 (Usd Million) 77
Table 101 Rest Of Europe: Metastases Spinal Tumor Market, For Surgical Treatment, By Type, 2019–2030 (Usd Million) 77
Table 102 Rest Of Europe: Metastases Spinal Tumor Market, By End User, 2019–2030 (Usd Million) 77
Table 103 Major Players In The Us And Europe Metastases Spinal Tumor Market 78
Table 104 Most Active Player In The Us And Europe Metastases Spinal Tumor Market 80
Table 105 Product Approval And Product Launch: Us And Europe Metastases Spinal Tumor Market 81
Table 106 Ge Healthcare: Products Offered 84
Table 107 Ge Healthcare: Key Developments 85
Table 108 Siemens Healthineers Ag: Products Offered 87
Table 109 Shimadzu Corporation: Products Offered 90
Table 110 Zimmer Biomet: Products Offered 93
Table 111 Johnson & Johnson Services, Inc: Products Offered 96
Table 112 Merit Medical Systems: Products Offered 99
Table 113 Amgen Inc.: Products Offerings 102
Table 114 Stryker: Products Offered 106
Table 115 Stryker: Key Developments 106
Table 116 Medtronic Plc: Products Offered 109
Table 117 Brainlab Ag: Products Offered 111
List Of Figures
Figure 1 Market Synopsis 13
Figure 2 Us And Europe Metastases Spinal Tumor Market 15
Figure 3 Bottom-up And Top-down Approaches 21
Figure 4 Market Dynamics: Analysis Of The Us And Europe Metastases Spinal Tumor Market 24
Figure 5 Driver Impact Analysis 25
Figure 6 Restraint Impact Analysis 26
Figure 7 Value Chain Analysis: Us And Europe Metastases Spinal Tumor Market 28
Figure 8 Porter's Five Forces Analysis: Us And Europe Metastases Spinal Tumor Market 30
Figure 9 Us And Europe Metastases Spinal Tumor Market, Type, Segment Attractiveness, (Usd Million) 34
Figure 10 Us And Europe Metastases Spinal Tumor Market, By Type, 2022 & 2030 (Usd Million) 34
Figure 11 Us And Europe Metastases Spinal Tumor Market Share (%), By Type, 2022 35
Figure 12 Us And Europe Metastases Spinal Tumor Market, Diagnosis & Treatment Segment Attractiveness, (Usd Million) 38
Figure 13 Us And Europe Metastases Spinal Tumor Market, By Diagnosis & Treatment, 2022 & 2030 (Usd Million) 38
Figure 14 Us And Europe Metastases Spinal Tumor Market Share (%), By Diagnosis & Treatment, 2022 39
Figure 15 Us And Europe Metastases Spinal Tumor Market, End User Segment Attractiveness, (Usd Million) 49
Figure 16 Us And Europe Metastases Spinal Tumor Market, By End User, 2022 & 2030 (Usd Million) 49
Figure 17 Us And Europe Metastases Spinal Tumor Market Share (%), By End User, 2022 50
Figure 18 Us & Europe: Metastases Spinal Tumor Market, By Region/Country, 2022 & 2030 (Usd Million) 52
Figure 19 Us & Europe: Metastases Spinal Tumor Market Share (%), By Region/Country, 2022 53
Figure 20 Us Market Analysis: Metastases Spinal Tumor Market, 2019-2030 (Usd Million) 54
Figure 21 Europe Market Analysis: Metastases Spinal Tumor Market, 2019-2030 (Usd Million) 57
Figure 22 Europe: Metastases Spinal Tumor Market, By Country, 2022 & 2030 (Usd Million) 58
Figure 23 Europe: Metastases Spinal Tumor Market Share (%), By Country, 2022 59
Figure 24 Benchmarking Of Major Competitors 79
Figure 25 Major Strategy Adopted By Key Players In The Us And Europe Metastases Spinal Tumor Market 80
Figure 26 Major Players Sales, 2022 81
Figure 27 Major Players R&D Expenditure, 2022 82
Figure 28 Ge Healthcare: Financial Overview Snapshot 84
Figure 29 Ge Healthcare: Swot Analysis 85
Figure 30 Siemens Healthineers Ag: Financial Overview Snapshot 87
Figure 31 Shimadzu Corporation: Financial Overview Snapshot 90
Figure 32 Zimmer Biomet: Financial Overview Snapshot 93
Figure 33 Zimmer Biomet: Swot Analysis 94
Figure 34 Johnson & Johnson Services, Inc: Financial Overview Snapshot 96
Figure 35 Merit Medical Systems: Financial Overview Snapshot 99
Figure 36 Merit Medical Systems: Swot Analysis 100
Figure 37 Amgen Inc.: Financial Overview Snapshot 102
Figure 38 Stryker: Financial Overview Snapshot 105
Figure 39 Stryker: Swot Analysis 107
Figure 40 Medtronic Plc: Financial Overview Snapshot 109
Figure 41 Medtronic Plc: Swot Analysis 110

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us